FDA Adverse Event Injury Summary report: N

ALINITY I TACROLIMUS REAGENT KIT

MDR report key: 18817798 · Received March 1, 2024

Report

Report Number
1415939-2024-00011
Event Type
Injury
Date Received
March 1, 2024
Date of Event
February 8, 2024
Report Date
April 11, 2024
Manufacturer
ABBOTT LABORATORIES
Product Code
MLM
UDI-DI
00380740154516
PMA / PMN Number
K070820
Adverse Event
Yes
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
SP
Reporter Occupation
OTHER HEALTH CARE PROFESSIONAL
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

SECTION A1 - PATIENT IDENTIFIER: SIDS (B)(6). AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE.

Additional Manufacturer Narrative · 0

SECTION B5 - DESCRIBE EVENT OR PROBLEM: THIS SECTION WAS UPDATED WITH ADDITIONAL INFORMATION PROVIDED BY THE CUSTOMER ON 07MAR2024. AN EVALUATION IS IN PROCESS. A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE EVALUATION IS COMPLETE.

Additional Manufacturer Narrative · 0

THE COMPLAINT INVESTIGATION FOR FALSELY ELEVATED ALINITY I TACROLIMUS RESULT INCLUDED A REVIEW OF DATA AND INFORMATION PROVIDED BY THE CUSTOMER, SEARCH FOR SIMILAR COMPLAINTS, TICKET TRENDING REVIEW, DEVICE HISTORY RECORD REVIEW, AND LABELING REVIEW. IN ADDITION, IN-HOUSE TESTING OF RETAINED REAGENT KIT WAS ALSO COMPLETED. RETURN TESTING WAS NOT COMPLETED AS RETURNS WERE NOT AVAILABLE. THE DATA AND INFORMATION PROVIDED BY THE CUSTOMER WERE REVIEWED AND SUPPORT THE COMPLAINT ISSUE. A TICKET SEARCH BY LOT INDICATES THE REAGENT LOT IS PERFORMING AS EXPECTED FOR THIS PRODUCT. A REVIEW OF THE COMPLAINT TRENDING REPORT DID NOT IDENTIFY ANY TRENDS FOR THE ISSUE FOR THE PRODUCT. A REVIEW OF THE DEVICE HISTORY RECORD DID NOT IDENTIFY ANY NON-CONFORMANCES OR DEVIATIONS WITH LOT 56743FP00 AND COMPLAINT ISSUE. AN ACCURACY TESTING WAS COMPLETED USING AN IN-HOUSE RETAINED REAGENT KIT OF LOT 56743FP00 STORED AT THE RECOMMENDED STORAGE CONDITION. THE TESTING MEETS ALL VALIDITY AND ACCEPTANCE CRITERIA. A REVIEW OF LABELING WAS PERFORMED AND FOUND TO SUFFICIENTLY ADDRESS THE CUSTOMER'S ISSUE. BASED ON THE REVIEW OF THIS ISSUE, USE ERROR MAY HAVE CONTRIBUTED TO THE CUSTOMERS ISSUE AS THE COMPLAINT NOTES INDICATE THE PREPROCESSING (PIPETTES, TIPS, ETC.) ARE QUITE OLD AND ADDED TO TECHNICIAN INEXPERIENCE, COULD HAVE CAUSED THESE DISCREPANCIES. BASED ON THIS INVESTIGATION, NO SYSTEMIC ISSUE OR DEFICIENCY WAS IDENTIFIED FOR THE ALINITY I TACROLIMUS REAGENT LOT 56743FP00.

Description of Event or Problem · 0

THE CUSTOMER REPORTED FALSELY ELEVATED ALINITY I TACROLIMUS RESULT GENERATED ON THE ALINITY I PROCESSING MODULE FOR A PATIENT. THE RESULT WAS RELEASED OUT OF THE LAB. THE FOLLOWING DATA WAS PROVIDED: PATIENT 2: ON (B)(6) 2024, SID (B)(6) , RESULT = 18.3 NG/ML. ON (B)(6) 2024 ,SID (B)(6) , RESULT = 9.1 NG/ML. THE CUSTOMER STATED THAT DUE TO THE FALSELY ELEVATED ALINITY I TACROLIMUS RESULT, UNNECESSARY BIOPSY WAS PERFORMED ON THE PATIENT. ADDITIONAL INFORMATION REGARDING THE BIOPSY WAS REQUESTED; HOWEVER, TO DATE, IT HAS NOT BEEN PROVIDED AND/OR RECEIVED. THERE WAS NO FURTHER IMPACT TO PATIENT MANAGEMENT REPORTED.

Description of Event or Problem · 0

UPDATE: ON 07MAR2024, THE CUSTOMER PROVIDED ADDITIONAL INFORMATION. THE SAMPLES WERE FROM A POST KIDNEY TRANSPLANT PATIENT AND THE BLOOD DRAW WAS TAKEN 24 HOURS AFTER THE MEDICATION WAS GIVEN. IT WAS NOTED THAT BOTH RESULTS WERE FROM THE SAME BLOOD DRAW. THERE WAS NO FURTHER IMPACT TO PATIENT MANAGEMENT REPORTED.

Description of Event or Problem · 0

THE CUSTOMER REPORTED FALSELY ELEVATED ALINITY I TACROLIMUS RESULT GENERATED ON THE ALINITY I PROCESSING MODULE FOR A PATIENT. THE RESULT WAS RELEASED OUT OF THE LAB. THE FOLLOWING DATA WAS PROVIDED: PATIENT 2: (B)(6) 2024 SID (B)(6) RESULT = 18.3 NG/ML. (B)(6) 2024 SID (B)(6) RESULT = 9.1 NG/ML. THE CUSTOMER STATED THAT DUE TO THE FALSELY ELEVATED ALINITY I TACROLIMUS RESULT, UNNECESSARY BIOPSY WAS PERFORMED ON THE PATIENT. ADDITIONAL INFORMATION REGARDING THE BIOPSY WAS REQUESTED; HOWEVER, TO DATE, IT HAS NOT BEEN PROVIDED AND/OR RECEIVED. THERE WAS NO FURTHER IMPACT TO PATIENT MANAGEMENT REPORTED. UPDATE: ON 07MAR2024, THE CUSTOMER PROVIDED ADDITIONAL INFORMATION. THE SAMPLES WERE FROM A POST KIDNEY TRANSPLANT PATIENT AND THE BLOOD DRAW WAS TAKEN 24 HOURS AFTER THE MEDICATION WAS GIVEN. IT WAS NOTED THAT BOTH RESULTS WERE FROM THE SAME BLOOD DRAW. THERE WAS NO FURTHER IMPACT TO PATIENT MANAGEMENT REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
2002193 ALINITY I TACROLIMUS REAGENT KIT ENZYME IMMUNOASSAY, TRACROLIMUS MLM ABBOTT LABORATORIES 56743FP00 00380740154516

Patients

Seq Age Sex Outcome Treatment
1 NA Unknown Disability ALNTY I PROCESSING MODU, 03R65-01, (B)(6)| ALNTY I PROCESSING MODU, 03R65-01, (B)(6)| ALNTY I PROCESSING MODU, 03R65-01, (B)(6)